Analysis of side effects of somituximab (Mirvetuximab)

Mirvetuximab (Mirvetuximab) has shown efficacy in the treatment of patients with FRα-positive advanced ovarian cancer, but it is also associated with certain side effects and requires strict clinical monitoring. Common side effects include blurred vision, nausea, diarrhea, fatigue, abdominal pain, corneal lesions, dry eyes, constipation, vomiting, decreased appetite, peripheral neuropathy, headache, weakness, elevated liver enzyme levels, and joint pain. These adverse reactions vary in frequency and severity in different patients, and some of them may affect more than 1/10 patients.

Some side effects are potentially serious and require prompt intervention. Clinically reported serious adverse events include pneumonia, small bowel obstruction, pleural effusion, abdominal pain, dehydration, constipation, nausea, ascites, and thrombocytopenia. These reactions may result in hospitalization or treatment modifications, and early identification and intervention are critical, especially in patients with long-term or multiple rounds of treatment. Doctors usually adjust the dosage, delay administration or provide symptomatic treatment based on the severity of side effects. For example, corneal lesions can be alleviated through ophthalmic intervention and artificial tears, while platelet decline requires monitoring of coagulation indicators and supportive care.

It is worth noting that the side effect mechanism of somituximab is related to the pharmacological characteristics of its antibody conjugate. The drug-conjugated cytotoxic component can selectively kill tumor cells with high expression of FRα, but some normal tissues may still be affected. For example, corneal epithelial cells express lower receptors, and local toxicity may also occur due to drug exposure. In addition, gastrointestinal symptoms such as nausea, diarrhea, and loss of appetite are mostly related to the effects of chemotherapy ingredients released by drugs on the intestinal mucosa.

In summary,Mirvetuximab shows good efficacy in FRα-positive advanced ovarian cancer, but it is accompanied by a certain risk of side effects. During use, patients need to closely monitor vision, liver function, blood indicators and nervous system status, and communicate with their doctors in a timely manner.

Reference materials:https://www.elahere.com/